D. Carbonell

Characterization of interferon-γ-treated melanoma tumor cells for use in dendritic cell-based immunotherapy.

R. Dillman, A. Cornforth, A. Fowler, 2011, Cancer biotherapy & radiopharmaceuticals.

Establishment of stable cell lines for personalized melanoma cell vaccine

S. Selvan, R. Dillman, M. Ravindranath, 2010, Melanoma research.

Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival

R. Dillman, A. Cornforth, A. Fowler, 2010, Cancer Immunology, Immunotherapy.

Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy: A Randomized Phase II Trial of Dendritic Cells Versus Tumor Cells in Patients With Metastatic Melanoma

R. Dillman, T. Amatruda, A. Cornforth, 2012, Journal of immunotherapy.

Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.

Licheng Zeng, Punam Malik, J. Yee, 2004, Blood.

Monitoring response to treatment in melanoma patients: Potential of a serum glycomic marker

S. Selvan, R. Dillman, M. Ravindranath, 2008, International journal of cancer.

Increases in Serum TARC/CCL17 Levels Are Associated with Progression-Free Survival in Advanced Melanoma Patients in Response to Dendritic Cell-Based Immunotherapy

R. Dillman, A. Cornforth, A. Fowler, 2009, Journal of Clinical Immunology.

Abstract 3703: Randomized trial of autologous dendritic cell vs tumor cell vaccines in patients with metastatic melanoma

R. Dillman, T. Amatruda, A. Cornforth, 2012 .